Jacobs Levy Equity Management’s Oragenics OGEN Stock Holding History

Jacobs Levy Equity Management’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1	Closed	-$15K	–	843
2015 Q1	$15K	Hold	1	–	–	﹤0.01%	774
2014 Q4	$16K	Sell	1 -1	-50%	-$17.4K	﹤0.01%	806
2014 Q3	$34K	Buy	+2	New	+$59.7K	﹤0.01%	807

Other funds holding OGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jacobs Levy Equity Management's OGEN Position: Q2 2015 in Review

Jacobs Levy Equity Management sold out of Oragenics (OGEN) in Q2 2015, closing a stake of 1 share — an estimated $15K sold.

Jacobs Levy Equity Management first reported a position in OGEN in Q3 2014 and held it in 3 quarters. The position peaked at $34K in Q3 2014. 7 funds tracked by Wall St. Rank hold OGEN as of Q2 2015.

Jacobs Levy Equity Management reported no remaining Oragenics position as of Q2 2015 after selling out during the quarter.
Jacobs Levy Equity Management sold 1 Oragenics share in Q2 2015, an estimated $15K.
Jacobs Levy Equity Management first reported a position in Oragenics in Q3 2014 and held it in 3 quarters.
Jacobs Levy Equity Management's Oragenics position peaked at $34K in Q3 2014.
7 funds tracked by Wall St. Rank held Oragenics as of Q2 2015.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2015, filed 14 Aug 2015.